Archived explainer. For the current picture see today's GMAB page.
GENMAB A/S ADR (GMAB) is up +12.23% in the latest session. Our newswire has captured 9 stories on GMAB across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Genmab A/S ADR (GMAB) surged 12.23% to $39.00 on October 5, 2026, driven by a series of positive developments across its clinical pipeline. The stock opened with a modest 1.3% gap up and climbed steadily throughout the session, reaching a high of $39.30 before settling near its peak. The move reflects investor optimism over recent data from Genmab’s trials and upgraded analyst expectations.
Genmab announced new data from its Rina-S Phase 1/2 RAINFOL-01 Part C trial, showing a 45.9% objective response rate in patients with platinum-resistant ovarian cancer. The results also indicated that 51% of responders remained in response after one year, with activity observed regardless of FRα expression levels. These findings highlight the drug’s potential in a difficult-to-treat patient population. Additionally, Genmab reported that its bispecific antibody epcoritamab, when combined with R-CHOP, demonstrated statistically significant improvement in progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients in the EPCORE DLBCL-2 Phase 3 study.
Analyst activity also contributed to the rally. Guggenheim raised its price target for Genmab to $54 from $45, citing the company’s pipeline potential. HC Wainwright & Co. reiterated its Buy rating with a $40 price target. Meanwhile, Darwin Global Management disclosed a 5.11% stake in Genmab, controlling 3,188,361 shares as of September 28, 2026.
The stock’s intraday performance showed strong momentum, with volume reaching 5.8 million shares, 2.5 times the 3-month average. The session high of $39.30 marked a new 52-week high, as the stock crossed above its prior 52-week peak of $35.91. Over the last 8 sessions, the stock had already risen 3.3% from $34.83 to $35.99. The 30-day average sentiment has improved from 57/100 to 61/100, reflecting growing positive sentiment.
Investors will likely continue to monitor Genmab’s clinical progress, particularly for Rina-S and epcoritamab. Analyst coverage and institutional ownership changes may also influence the stock’s near-term direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and...
Genmab disclosed that Darwin Global Management Limited controls voting rights attached to 3,188,361 shares—5.11% of Genmab’s voting rights—as of September 28, 2026. The announcement is a regulatory major-shareholder notice rather than a business or pipeline update, with GMAB trading at $35.70 as of 11:04 AM.
Guggenheim raises Genmab stock price target on pipeline potential
Genmab reported Phase 1/2 RAINFOL-01 Part C results showing a confirmed 45.9% objective response rate for investigational ADC Rina-S in 109 patients with platinum-resistant ovarian cancer, with a 12.1-month median duration of response and 51% of responders still in response at one year. The company also reported a 9.5-month median progression-free survival and said activity was observed regardless of FRa expression level, including low and non-expressors, as multiple Phase 3 trials continue.
Why is Genmab stock rallying today?
Genmab shares jump as ovarian cancer drug shows durable responses in trial
More on GMAB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GMAB move explainers: 2026-10-05